BioDelivery Sciences (BDSI) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
BioDelivery Sciences Provides Corporate Update and Reports First Quarter 2016 Financial Results
May 10, 2016 7:00 AM EDTRALEIGH, N.C., May 10, 2016 /PRNewswire/ --
Strategic initiatives implemented to better align BUNAVAIL® expenses with revenue as part of ongoing efforts to preserve and enhance long-term value; changes expected to result in savings of approximately $20 million through 2017 BUNAVAIL prescriptions increase 180% compared to first quarter of 2015; over 350 new prescribers added in first quarter of 2016 BUNAVAIL net revenue increased 41% in first quarter compared to fourth quarter 2015 BUNAVAIL revenue per prescription increased more than 20% in the first quarter compared to fourth quarter 2015 Strong cash position of $69.4... More


